Drug Profile
CBA 1205
Alternative Names: CBA 1205; LIV-1205Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Chiome Bioscience; LivTech
- Developer ADC Therapeutics; Chiome Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Mitogen-activated protein kinase kinase kinase 12 modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Liver cancer
Most Recent Events
- 28 Aug 2023 Phase I development in solid tumour is ongoing in Japan (Chiome Bioscience pipeline, August 2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Japan (IV, Infusion)
- 14 Apr 2023 Preclinical trials in Liver cancer in Japan (Intraperitoneal) prior to April 2023